<DOC>
	<DOCNO>NCT00204581</DOCNO>
	<brief_summary>The intra-/perilesional application interleukin-2 seem safe effective treatment skin soft tissue metastasis malignant melanoma . Especially case intransit metastases overall survival rate still 20-30 % . However , management intransit metastases sometimes difficult frequent recurrence . IL-2 intralesionally seem non-invasive option pilot study indicate . In study safety efficacy IL-2 evaluate .</brief_summary>
	<brief_title>Intralesional Treatment With Interleukin-2 ( Proleukin ) Soft Tissue Melanoma Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age 18+ Informed consent Histologically proven melanoma Have confirm stage IIIB stage IV disease ( AJCC 2002 ) skin softtissue metastasis Pregnant lactate woman Patients severe cardiac disease ( e.g . NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina ) Patients severe liver disease severe renal disease Simultaneous immunosuppressive treatment ( e.g . steroid ) Simultaneous chemotherapy Pretreated softtissue skin metastasis ( e.g . cryo , radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Soft tissue metastasis</keyword>
	<keyword>Interleukin-2</keyword>
</DOC>